Literature DB >> 12238936

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis.

Takashi Miki1, Masakuni Kori, Hiroshi Mabuchi, Ryu-ichi Tozawa, Tomoyuki Nishimoto, Yasuo Sugiyama, Koichiro Teshima, Hidefumi Yukimasa.   

Abstract

Modification of the carboxyl group at the 3-position and introduction of protective groups to the hydroxy group of the 4,1-benzoxazepine derivative 2 (metabolite of 1) were carried out, and the inhibitory activity for squalene synthase and cholesterol synthesis in the liver was investigated. Among these compounds, the glycine derivative 3a and beta-alanine derivative 3f exhibited the most potent inhibition of squalene synthase prepared from HepG2 cells (IC(50) = 15 nM). On the other hand, the piperidine-4-acetic acid derivative 4a, which was prepared by acetylation of 3j, was the most effective inhibitor of cholesterol synthesis in rat liver (ED(50) = 2.9 mg/kg, po). After oral administration, 4a was absorbed and rapidly hydrolyzed to deacylated 3j. Compound 3j was detected mainly in the liver, but the plasma level of 3j was found to be low. Compounds 3j and 4a were found to be competitive inhibitors with respect to farnesyl pyrophosphate. Further evaluation of 4a as a cholesterol-lowering and antiatherosclerotic agent is underway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12238936     DOI: 10.1021/jm020234o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate.

Authors:  Ali Koohang; Jessica L Bailey; Robert M Coates; Hans K Erickson; David Owen; C Dale Poulter
Journal:  J Org Chem       Date:  2010-07-16       Impact factor: 4.354

2.  Rhodium-catalyzed enantioselective silylation of arene C-H bonds: desymmetrization of diarylmethanols.

Authors:  Taegyo Lee; Tyler W Wilson; Robert Berg; Per Ryberg; John F Hartwig
Journal:  J Am Chem Soc       Date:  2015-05-20       Impact factor: 15.419

3.  Discovery of DF-461, a Potent Squalene Synthase Inhibitor.

Authors:  Masanori Ichikawa; Masami Ohtsuka; Hitoshi Ohki; Masahiro Ota; Noriyasu Haginoya; Masao Itoh; Yoshihiro Shibata; Yutaka Ishigai; Koji Terayama; Akira Kanda; Kazuyuki Sugita; Hiroyuki Usui
Journal:  ACS Med Chem Lett       Date:  2013-09-04       Impact factor: 4.345

4.  Squalene synthase inhibition: a novel target for the management of dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

5.  Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Authors:  Tomoyuki Nishimoto; Yuichiro Amano; Ryuichi Tozawa; Eiichiro Ishikawa; Yoshimi Imura; Hidefumi Yukimasa; Yasuo Sugiyama
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

6.  Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.

Authors:  M Shiomi; S Yamada; Y Amano; T Nishimoto; T Ito
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

7.  5-Chloro-2-hy-droxy-benzoic acid.

Authors:  Abdul Rauf Raza; Bushra Nisar; M Nawaz Tahir; Ahmad Raza
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-10-23

8.  Copper-Catalyzed Borylative Aromatization of p-Quinone Methides: Enantioselective Synthesis of Dibenzylic Boronates.

Authors:  Carlos Jarava-Barrera; Alejandro Parra; Aurora López; Fabio Cruz-Acosta; Daniel Collado-Sanz; Diego J Cárdenas; Mariola Tortosa
Journal:  ACS Catal       Date:  2015-12-11       Impact factor: 13.084

Review 9.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

10.  Anti-inflammatory and cytoprotective effects of a squalene synthase inhibitor, TAK-475 active metabolite-I, in immune cells simulating mevalonate kinase deficiency (MKD)-like condition.

Authors:  Nobutaka Suzuki; Tatsuo Ito; Hisanori Matsui; Masayuki Takizawa
Journal:  Springerplus       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.